This trial is evaluating whether Oncoquest-CLL vaccine will improve 3 primary outcomes and 5 secondary outcomes in patients with Leukemia, Lymphoid. Measurement will happen over the course of Up to 4 weeks..
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Oncoquest-CLL Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Today's chemotherapy regimens have improved tremendously. In modern medical practice, a cure of leukemia is not achievable. A cure does not exist among chronic lymphocytic leukemia patients. Leukemia, lymphocytic, chronic, b-cell is not curable. The current treatment options are only palliative." - Anonymous Online Contributor
"A number of treatments for leukemia, lymphocytic, and related conditions have been developed and are used and many of these are still under study with a goal to identify those most effective and to help select less toxicity. The list of treatments for these diseases is growing and will be expanding with improved understanding of the disease process and treatment regimens. This article illustrates the treatments used to treat some cancers, while other articles in this section go into the pathology of the diseases, and treatments used. The most common treatments are summarized in Table 1." - Anonymous Online Contributor
"Approximately 40,000 people are diagnosed with [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) each year. Around 3,000 people are diagnosed with acute myeloid (leukemia) each year, and 5,000 with acute lymphocytic (chronic lymphocytic) leukemia." - Anonymous Online Contributor
"Most cases involve defects in the immune system, and are most likely to occur after a person has been exposed to certain environmental hazards, or heredity." - Anonymous Online Contributor
"Leukemia, lymphocytic, chronic, b-cell, a blood or bone marrow cancer is the most common cancer among patients with SLE. However, since other hematologic and oncologic diseases can present with the same symptoms as and have a similar course to SLE, it often goes unrecognized or undiagnosed." - Anonymous Online Contributor
"Signs of leukemia include an enlarged spleen in 30% of cases, a low platelet count in 15% of cases, and elevated red blood cell count. Signs of lymphocytic leukemia include a high lymphocyte count in 15% (20% of cases), a decreased red cell count in 3% (20% of cases), and a low platelet count in 3% (10% of cases)." - Anonymous Online Contributor
"Many patients with [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) develop secondary primary chronic myelogenous leukemia due to an error during hematopoietic stem cell transplantation as a result of primary chronic myelogenous leukemia. Lymphoid leukemia, chronic lymphocytic, B-cell, and chronic myelogenous are classified into one syndrome. The diagnosis may not be made until lymphoid or myeloid leukemia develops years after transplantation. These patients present with the new syndrome as well. Primary chronic myelogenous leukemia often follows one of the secondary cancers, i.e., lymphoid or myeloid." - Anonymous Online Contributor
"This is probably the fastest leukemia I have seen in some years, but I have not yet been able to measure this in detail due to delays in the processing of blood samples. Also, as this was a single patient, I cannot be sure how representative the results are (this is more likely in a real clinical setting). However, based on past reports, it probably translates into a median time of 24 to 73 days. Lymphocytic, chronic, b-cell spread occurs within the first 7 days of diagnosis in this case. Patients with a history of chemotherapy were more likely to die from leukemia, lymphocytic, chronic, b-cell cancer than patients with a history of leukemia without chemotherapy." - Anonymous Online Contributor
"In recent months the use of bortezomib in combination with other chemotherapies has gained significant interest as a treatment for B-cell malignancies, particularly low-risk diffuse large B-cell lymphomas. The addition of bortezomib plus mitoxantrone is also a novel treatment approach for low-risk, unfavorable indolent follicular lymphomas. Trials with this combination will continue into 2019." - Anonymous Online Contributor
"Individuals previously treated with B-cell depletion therapies are more frequently vaccinated with OVCLL than previously diagnosed participants. However, the vaccine was not associated with any allergic reactions or serious side effects." - Anonymous Online Contributor
"The treatment of refractory/relapsed/sensitive CLL patients with oncoquest-cll and/or chemotherapy resulted mainly in stable disease rates comparable to chemotherapy. However, the combined therapy with oncoquest-cll and bortezomib resulted in prolonged progression-free survival rates similar to other studies and the single-agent-oncoquest regimen." - Anonymous Online Contributor
"OC-CLL is well tolerated and is associated with significant improvement in QOL among patients with lymphocytic cancers. These data provide an exciting rationale for a broader trial of OC-CLL in a more heterogeneous patient population." - Anonymous Online Contributor